Longevity Services & Practice Library
Every article, presentation, spotlight, and news item we've tagged to Longevity Services & Practice.
Showing 97–120 of 235
Updating risk models with real-world data
Longevity AI and Meir Medical Center are updating classical cardiovascular and metabolic disease risk models using contemporary real-world clinical data to improve early detection accuracy. This approach prioritizes practical prevention of the diseases causing the largest population-level health loss, rather than pursuing experimental aging interventions.
The hidden bottleneck in longevity biotech
Longevity biotech's bottleneck lies not in laboratory science but in financial infrastructure—fragmented systems and delayed data visibility cause promising therapies to be shelved despite scientific merit. Unified financial platforms that integrate clinical, operational, and budgetary data in real time can accelerate therapeutic development by improving allocation decisions and reducing administrative friction.
Why the wellness industry needs a new operating system
The wellness industry operates on infrastructure designed for episodic experiences rather than sustained behavioral change over decades. Longevity now requires systems-based approaches that embed healthy behaviors into everyday environments and social contexts, not temporary interventions delivered in specialized settings.
Amazon makes longevity move with Lifeforce collab
Amazon One Medical has integrated Lifeforce's biomarker analysis into its primary care platform, offering members personalized health insights derived from over 50 standard lab biomarkers organized by health domains. This integration represents a significant expansion of preventive medicine tools into mainstream primary care, positioning biomarker-driven interpretation as a foundational element of personalized health management.
XPRIZE Healthspan: Functional Recovery Trials Begin
XPRIZE Healthspan has advanced 20 finalists to clinical trials within its $101 million competition, with ten teams receiving $1 million each to test interventions targeting age-related decline in muscle, cognitive, and immune function. The transition from preclinical promise to coordinated human trials represents a critical inflection point: therapeutic mechanisms now must demonstrate measurable functional restoration in adults aged 50–90 within one year.
Evidence Infrastructure Closes Longevity Interpretation Gap
Evipedia provides structured, regularly updated evidence reviews for over 500 health and longevity interventions, addressing a critical infrastructure gap in the longevity field. As intervention options proliferate faster than reliable evaluation frameworks, this resource helps practitioners and consumers distinguish established evidence from speculative claims.
Estrogen Receptor Agonist Advances to Federal Lifespan Testing
LNS8801, a selective estrogen receptor agonist developed by Linnaeus Therapeutics, has been selected for lifespan testing by the National Institute on Aging's Interventions Testing Program, with concurrent federal funding to evaluate its effects on functional capacity and age-related decline. The drug's progression from oncology trials to dedicated longevity research reflects emerging evidence that certain receptor pathways may influence both disease prevention and healthspan preservation.
Data without decisions: Why biomarkers alone fail
Wearable technology and biomarker testing provide detailed health data, but information alone does not drive behavior change. Effective health optimization requires prioritized decision-making and strategic intervention selection, not data accumulation.
Loyal raises $100m Series C to advance canine longevity drug
Loyal secured $100 million Series C funding to advance LOY-002, a prescription medication designed to extend healthy lifespan in senior dogs by targeting metabolic pathways associated with aging. The drug has completed enrollment in its pivotal clinical trial and represents a potential first-in-species FDA-authorized longevity therapeutic.
20/20 BioLabs expands longevity test with kidney risk tech
20/20 BioLabs has licensed ROKIT Healthcare's chronic kidney disease prediction algorithm to expand its longevity testing platform beyond inflammation markers into earlier risk detection. The addition addresses a substantial gap: over 35 million Americans have chronic kidney disease, yet most remain unaware until significant progression occurs, making early identification clinically actionable for preventing age-related decline.
ARPA-H pours millions into healthspan-focused human trials
ARPA-H is allocating $144 million through its PROSPR program to fund seven research teams testing interventions designed to extend healthspan in humans. The initiative addresses a critical gap in geroscience drug development by establishing early biomarkers and trial designs that can demonstrate functional benefit within one to three years rather than decades.
Digital Engagement and Successful Aging: A Longitudinal Analysis of Older Adults in China
Digital engagement demonstrates bidirectional associations with successful aging in Chinese adults aged 60–75 over seven years, with baseline digital use predicting improvements in physical function, cognitive performance, and subjective well-being, while successful aging outcomes also predict sustained digital engagement. This longitudinal evidence suggests digital literacy and consistent technology use function as modifiable factors supporting multiple dimensions of aging outcomes.
Serotonin Anti-Aging Center to open Lake Nona location this spring
Serotonin Anti-Aging Centers is expanding to Lake Nona, Florida in spring 2026, adding to its national footprint of longevity and hormone optimization clinics. The expansion reflects growing consumer demand for preventive wellness services, though the article focuses on business development rather than clinical evidence.
Longevity Outcomes Depend on System Integration, Not Innovation Supply
Canada's transition to super-aged status by 2026 has prompted institutional action on longevity as a structural challenge rather than a future concern. Manulife and the World Economic Forum are launching an innovation challenge focused on three interconnected dimensions—healthy aging, financial resilience, and social connection—with emphasis on solutions that integrate into existing systems rather than operating parallel to them.
SIRIO Europe rolls out new habit-first longevity platform
SIRIO Europe launched Aeion, a habit-first longevity platform that prioritizes consistent daily rituals over complex protocols, addressing the persistent gap between longevity innovation and real-world adoption. The platform delivers eight supplement concepts through friction-reducing formats designed to support energy, mobility, cardiovascular function, and inflammatory aging management.
Revive expands access to physical therapy via Orbit telehealth partnership
ReviveHealth integrated virtual physical therapy through Orbit Telehealth, consolidating therapy access within a single coordinated care platform alongside primary care, mental health, and pharmacy services. This addresses a structural barrier to rehabilitation—fragmented access—that undermines consistent participation in movement-based interventions critical to maintaining functional capacity and independence across the lifespan.
Virtual assistant enhances health outcomes in older adults with type 2 diabetes
A randomized controlled trial found that older adults with type 2 diabetes using a conversational AI virtual assistant achieved significantly better glycemic control and medication adherence compared to standard care. The intervention demonstrates that digital tools can reduce barriers to diabetes management in aging populations.
YOU(th) lands funding for smartphone-based preventive health screening
YOU(th) has secured $4.5 million to advance a smartphone-based screening platform that analyzes facial video, voice, eye images, and movement patterns to assess over 50 digital biomarkers across multiple organ systems in under two minutes. The approach aims to reduce friction in preventive health screening by leveraging ubiquitous smartphone sensors to detect physiological and metabolic signals outside traditional clinical settings.
Serotonin Anti-Aging Centers signs multi-location expansion deal in North Texas
Serotonin Anti-Aging Centers is expanding its hormone optimization and longevity clinic network with five new locations in North Texas. The expansion reflects growing consumer demand for personalized preventive health and age-management medicine delivered through standardized clinical protocols.
Isaac Health partners with NYU Langone to expand brain health care access
Isaac Health and NYU Langone have established a telehealth partnership to accelerate access to dementia and cognitive evaluation services, addressing critical delays in specialist availability across New York state. The hybrid model reduces diagnostic timelines from months to days while maintaining the option for in-person intervention when clinically indicated.
Developing a Genetic Algorithm-Based Frailty Index for China Health and Retirement Longitudinal Study
Researchers developed a genetic algorithm-based frailty index using nine years of longitudinal data from the China Health and Retirement Longitudinal Study to predict mortality and falls risk in aging adults. This computational approach identifies which physiological and functional markers most reliably indicate vulnerability to adverse outcomes, providing a data-driven alternative to subjective clinical assessment.
Systemic Care Design Shapes Longevity Outcomes
Person-centered care in long-term settings operates across three interconnected levels—individual interactions, institutional structure, and societal systems—rather than as isolated clinical encounters. Optimizing outcomes requires aligning practices across all three levels simultaneously, addressing how systemic constraints either enable or undermine the quality of care delivery.
Loyal raises $100m as canine longevity drug nears approval
Loyal has raised $100 million in Series C funding as its lead candidate LOY-002, designed to extend healthy lifespan in dogs, approaches FDA Expanded Conditional Approval. The company has completed two of three major technical requirements and enrolled over 1,300 dogs in its pivotal STAY trial, positioning the first potential FDA-approved longevity drug for market readiness.
Could Ginkgo’s OpenAI collab accelerate progress in longevity?
An autonomous laboratory system combining GPT-5 reasoning with Ginkgo's cloud infrastructure executed over 36,000 cell-free protein synthesis experiments in six months, reducing production costs by 40% while maintaining experimental rigor. This approach addresses a primary constraint in longevity research: the ability to test sufficient hypotheses at scale and speed without proportional increases in cost and human labor.